Please enable JavaScript.

Coggle requires JavaScript to display documents.

OVARIJ (Target (PARP (INDIKACIJE (https://www.google.com/search?q=parp+inh…

- - - - VEGF
        
        nakon OP
        
        studije
        
        ICON 7, 900 PTS, hr 0.87 (ci0.99), pfs 17 VS 20 mj, bev 12 mj(18 ckl), st I-IV
        
        subanaliza, benefit OS (39 vs 30 mj), st III 1000 pts (290 R>1cm, 10 bez OP), st IV 200 pts; ZNAČI: st IV, suboptimal debulking ili bez OP
        
        GOG 218, krivulja kao ICON7, st III-IV
        
        dizajn
        
        https://www.google.com/search?q=gog+218&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiY-KnCndLrAhW4QkEAHYrlANwQ_AUoAXoECAsQAw&biw=1536&bih=722#imgrc=qwPvU_kHjzEzZM
        
        https://www.google.ba/search?q=icon+7+vs+gog+218&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjC4YL29rzZAhXGDOwKHbUCAygQ_AUICigB&biw=1229&bih=607#imgrc=2WAImZkYORRw9M:
        
        stariji
        
        studija
        
        ROSiA, I(G3)-IV, dozvoljena neo, , <70y 900pts vs >70 120 pts, AE SS u stariji, gr 3 hip 40 vs 20%, TE 4vs2%
        
        TKI
        
        nin
        
        pazo
    - - VEGF
        
        senzitivni
        
        studije
        
        OCEANS, PFS, ne bev prije,, gem, placebo DA
        
        GOG213, OS, 10% prije bev, pakli, placebo NE
        
        https://www.youtube.com/watch?v=BJ6mKz1tZpo
        
        u tijeku, OV17, Carbo+Pakl vs GEm vs PLD- 6 ckl +bev do PD
        
        refraktorni
        
        AURELIA, PLD, Tax, Topo, PFS 6.7 vs 3.4, HR 0.48 (C0.60), OS 16 vs 13 mj NSS, ORR 50% Pakli, 2 ostala oko 20%, SS manje simptoma i ascitesa
        
        mednet
        
        Bevacizumab
        
        platinum senzitivni
        
        mnemo
        
        CIAO
        
        zbirno studije
        
        https://ecancer.org/en/journal/article/626-targeted-agents-in-epithelial-ovarian-cancer-review-on-emerging-therapies-and-future-developments
  - - - PARP
        
        vrste
        
        veliparib
        
        GOG, KT+/- veli, IC-IV st (nije naveden BRCA status)
    - - PARP
        
        lijekovi
        
        Olaparib
        
        studije
        
        ordinacija
        
        održavanje
        
        3 more items...
        
        2L
        
        Niraparib
        
        ordinacija
        
        održavanje
        
        frontline
        
        1 more item...
        
        održavanje
        
        1 more item...
        
        Rucaparib
        
        ordinacija
        
        održavanje
        
        pl senzitivni,
        
        1 more item...
        
        koliko
        
        6(ORN; veli, Talazo, mala molekula)
        
        veliparib
        
        GOG 3005
        
        https://clinicaltrials.gov/ct2/show/NCT02470585
        
        PARP
        
        studije
        
        https://www.google.ba/search?q=parp+inhibitor+study&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjOuOunkeraAhVmG5oKHX2nBYoQ_AUICigB&biw=1229&bih=548#imgrc=js65EgurqFmVLM:
        
        HRD
        
        TCGA 50%, 50% pts ima fekt PARP inhibicijom
        
        zajedničko
        
        održavanje
        
        studije (SOLO2, ARIEL3, NOVA)
        
        PFS kontrolne grane 5 mj nakon ordinacije dobleta (ZNAČI PD<6mj)
        
        randomizacija 2:1, HGS, TFIp <6mj
        
        doza 300 mg
        
        nira 1x
        
        ola 2x
        
        PFS
        
        SOLO2 , ARIEL3, NOVA - PFS kontrolne grane 5 mj nakon ordinacije dobleta (ZNAČI PD<6mj)
        
        g+s (NOVA) - BRCA mutirani+PARP
        
        1 more item...
        
        AE
        
        prekid <15%
        
        signifikatne (gr>3)AE<20%
        
        2 more items...
        
        smanjivanje doze
        
        1 more item...
        
        redukcija doze
        
        RADAR studija (<77kg, Tr<150) 40 vs 15%
        
        1 more item...
        
        platinum refraktorni
        
        ARIEL 4, uvjet BRCA 1 ili 2 mutiran, f3
        
        NCCN
        
        PARP
        
        Nira
        
        NOVA
        
        R
        
        1 more item...
        
        D
        
        1 more item...
        
        Ruca
        
        ARIEL2
        
        R
        
        D
        
        1 more item...
        
        Olaparib
        
        SOLO 2
        
        rezultati
        
        1 more item...
        
        dizajn
        
        1 more item...
    - - https://www.google.com/search?q=parp+inhibitor+and+ovarian+cancer+indication&source=lnms&tbm=isch&sa=X&ved=0ahUKEwichqfQy8jgAhUQ0xoKHWqkDwcQ_AUIDigB&biw=1229&bih=603#imgrc=-6swA-ReJWoLnM:
      - https://www.google.com/search?q=parp+inhibitor+and+ovarian+cancer+indication&source=lnms&tbm=isch&sa=X&ved=0ahUKEwichqfQy8jgAhUQ0xoKHWqkDwcQ_AUIDigB&biw=1229&bih=603#imgrc=8WapH9Z9FC-bKM:
    - - https://www.google.com/search?q=parp+inhibitor+trial+in+ovarian+cancer&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjXspfrzMjgAhUwxIsKHVQ_DpUQ_AUIDigB&biw=1229&bih=603#imgrc=q1P9VC6f-OSBfM:
  - - - ŠTO DATI
        
        dobket
        
        PFS
        
        PARP
        
        BRCA mut-20 mj, 80%
        
        WT (nira) 9 mj, RR 60%
        
        Bev 12-14 mj, RR 78%
  - - - Lurbinectidin
        
        brat Trabectedena
        
        MOA
        
        DSB
        
        deplecija TAM (TUMOR Asosieted Macrofaga koi rade zlo)
        
        povećavaju upalu (IL6..)
        
        imunosupresija
        
        povećanje angiogeneze
        
        proliferacija tumora
        
        studije
        
        pretetirani 23% (1CR) vs topo 0%
        
        CORAL, f3, vs Topo ili PLD
      - ADC
        
        Mirvetuxumab Sorvatensin
        
        MOA
        
        veže se na FR, uđe u stanicu, otpušta cistostatik (sličan Doxu)
        
        studije
        
        f2, pretretirani, RR 25% (FR visoki 28%
        
        FOEWARD, u tijeku
      - rehabilitacija p53
        
        PISARO
  - - - CPI
        
        PDL1
        
        Atezo
        
        2L, 25%
        
        1L, u tijeku IMagy50, KT+bev (imunosupresija, reducira TIL) vs KT+atezo+bev
        
        Durva
        
        2L, RR NN
        
        ne znam liniju, ENGOT OV 43 (ola+durva)
        
        MEDIOLA
        
        ola+durva, PS (pla senzitivni)
        
        PD1
        
        lijekovi
        
        Pembro KN28
        
        2L, RR10%
        
        ne znam liniju, DUO-O (ola (više neoantigena)+pembro)
        
        Nivo
        
        2L, RR15%
        
        Ave
        
        2L, RR10%
        
        1L, u tijeku Javelin Ovarian 100, 3 grupe pts (1 kt, 2kt održAve, 3 kt+a+održavanje)
        
        zajedničko 2L (3PD1 i 2PDL1) - više od 50% prethodno th, PD1 >80%, RR od 10 do 25%, 20 pts osim Ave 120 pts
- - - - 3 vrste
        
        površinski epitel 70%
        
        germ cell 20%
        
        SECTE
        
        https://radiopaedia.org/articles/germ-cell-tumours-mnemonic
        
        studije
        
        https://www.urotoday.com/images/ASCO_GU_2019_prospective_studies_Group_AGCT1531.JPG
        
        ssex cordtromal cell 10%
        
        MNEMONIC
        
        http://www.rxpgonline.com/medicalmnemonic913501.html
        
        ILUSTRACIJA
        
        https://www.google.com/search?q=sex+cord+stromal+ovarian+cancer&source=lnms&tbm=isch&sa=X&ved=2ahUKEwjFhda519HqAhXtsosKHWKOC9QQ_AUoAXoECAwQAw&biw=1920&bih=937#imgrc=8cwPocPiQRN9nM
      - podvrste
        
        sex cord
        
        typ 1, 2
        
        HG
  - - - https://www.google.com/search?q=staging+ovarian+cancer&source=lnms&tbm=isch&sa=X&ved=0ahUKEwiBspaai-bgAhXB-yoKHV2GCg4Q_AUIDigB&biw=1229&bih=603#imgrc=bsXMeZ3oo0OdFM:
    - - 2 studije
        
        UK
        
        PLCO
        
        https://www.google.ba/search?biw=1396&bih=641&tbm=isch&sa=1&ei=Uq3aW8aXHPCjrgTssY-4BQ&q=PLCO+study+ovarian+cancer&oq=PLCO+study+ovarian+cancer&gs_l=img.3...4764.5693.0.6027.2.2.0.0.0.0.384.384.3-1.1.0....0...1c.1.64.img..1.0.0....0.h7rf-wBCwAI#imgrc=5Nqh_TxMoEXYLM:
    - - BRCA
        
        somatski
        
        TCGA 1(4%), 2(3%)
        
        germline
        
        TCGA, 1(8%), 2(6%)
        
        Mostar
        
        parafinska kocka
        
        cijena 2500 KM
        
        1000 KM pacijent
- - - - radioatkivni izotopo
        
        WAI
        
        GOG 95-radioaktivni O vs kemoth-bolja KT (cis+ciklo)
  - - - https://ro-journal.biomedcentral.com/articles/10.1186/s13014-020-01564-w
    - - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4308098/
- - - - platini+taxani
        
        Cisplatni
        
        4 studije (GIGO-GOG 111, IVON3, GOG 132, OV10), od st I-IV, pts 300-600-2000; PFS 15-18 mj, OS 35-38 mj
        
        sumirane studije
        
        https://www.google.ba/search?q=gog+111,+icon+3&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjpsZeNg7jeAhWwqIsKHcXZDgoQ_AUIDigB&biw=1396&bih=686#imgrc=BwlJyYfjXqOWgM:
        
        razlike rezultata
        
        https://www.google.ba/search?q=gog+111,+icon+3&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjpsZeNg7jeAhWwqIsKHcXZDgoQ_AUIDigB&biw=1396&bih=686#imgrc=9Ih86_O-TZc3SM:
        
        pojedinačne dizajn
        
        OV 10
        
        https://www.google.ba/search?q=gog+158,+ago&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjNvfP7g7jeAhURlosKHTbGD28Q_AUIDigB&biw=1396&bih=686#imgrc=TriRqRgDjgtIGM:
        
        https://www.google.ba/search?q=gog+111&source=lnms&tbm=isch&sa=X&ved=0ahUKEwiy84mahLjeAhUFmYsKHT2RBGoQ_AUIDigB&biw=1396&bih=686#imgrc=NPovQPBImE9yvM:
        
        mnemo studije: GIGO
        
        carbo
        
        GAN (GOG 158, AGO, Nizozemska), 20 i 700 pts, PFS 16-20 mj, OS 30-40->50 mj
        
        GOG 158
        
        https://www.google.ba/search?q=gog+158&source=lnms&tbm=isch&sa=X&ved=0ahUKEwi5yevFhbjeAhVqlIsKHYdDArEQ_AUIDigB&biw=1396&bih=686#imgrc=Y28cW96Ejlgu6M:
        
        STARIJI
        
        EWOC 1
        
        https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.5508
      - INTRAPERITONEALNA
        
        studije
        
        uznapredovali
        
        2 studije, 800 pts, 10y FU
        
        GOG 172, 16 mj benefit, IP 3 grupe (6ckl, najbolji OS, 3-5 iv, <3 iv), samo IV
        
        GOG 114, OS 61 vs 51 mj
        
        dizajn zbir
        
        https://www.google.ba/search?q=gog+114,+172&source=lnms&tbm=isch&sa=X&ved=0ahUKEwiupvnth7jeAhVCw4sKHe47Cu8Q_AUIDygC&biw=1396&bih=686#imgrc=8srdzcBf1Lc67M:
        
        st II-III, R<1 cm ili R0
        
        GOG 252, PFS NSS (st II-27 mj), st III (32 mj), IP cis ili carbo vs IV
        
        dizajn
        
        https://www.google.ba/search?q=gog+252&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjww6GEh7jeAhWtp4sKHZOPCyEQ_AUIDigB&biw=1396&bih=686#imgrc=iFQTHX48MUfVMM:
        
        GOG 104, >500 pts, 49 vs 41 mj) ci IP+ciklIV, Cis+Cikl IV
        
        HIPEC vs IP
        
        https://www.themednet.org/question/7753
      - DD
        
        studije
        
        Katsumata, 637 pts, PFS 28 vs 17 mj, HR 0.71, OS 8 vs 5y
        
        ICON 8, standard vs tj Tax vs tj TC, PFS NSS, 18 vs 20 mj; OS NSS 16 vs 48 mj
        
        2 neg
        
        MITO 7
        
        https://www.google.ba/search?biw=1396&bih=686&tbm=isch&sa=1&ei=IIDdW6qLIKSyrgSY243gCA&q=mito+7+study+ovarian+cancer&oq=mito+7+study+ovarian+cancer&gs_l=img.3...59744.69367.0.69544.21.18.3.0.0.0.165.2033.0j18.18.0....0...1c.1.64.img..0.0.0....0.9d1-gnJf8sc#imgrc=jLF8VmZQ1b9CCM:
        
        GOG 262, + bev, bez beva poz PFS
        
        https://www.youtube.com/watch?v=EmxbECg2znQ
        
        dizajn
        
        https://www.google.ba/search?q=gog+262&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjP15TSibjeAhXysIsKHbAtAk8Q_AUIDigB&biw=1396&bih=686#imgrc=vcFi3P_ajX2suM:
        
        ACRIN 6695
        
        https://ascopubs.org/doi/abs/10.1200/jco.2012.30.15_suppl.tps5114
        
        koncept
        
        https://www.google.ba/search?q=dose+dense+ovarian+cancer+study&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjrmpzHiLjeAhXElYsKHdQLC5IQ_AUIDigB&biw=1396&bih=686#imgrc=TxDS4HFP2NE1bM:
        
        https://www.google.ba/search?q=mito+7+study&source=lnms&tbm=isch&sa=X&ved=0ahUKEwiiv7ShibjeAhXjkIsKHUoxBSQQ_AUIDigB&biw=1396&bih=686#imgrc=LmT1geEUho69fM:
        
        splitska
        
        http://sci-hub.tw/10.1093/jjco/hyz011
      - st I
        
        studije
        
        ACTION
        
        ICON 1
        
        rezultati zbir
        
        https://www.google.ba/search?biw=1396&bih=686&tbm=isch&sa=1&ei=NIHdW_nIB43PrgTo6proDA&q=action%2C+icon+1+study+ovarian+cancer&oq=action%2C+icon+1+study+ovarian+cancer&gs_l=img.3...8908.11217.0.11350.15.8.0.0.0.0.0.0..0.0....0...1c.1.64.img..15.0.0....0.b1mCVyn0uxQ#imgrc=y69NKJBZYjR16M:
        
        dizajn
        
        https://www.google.ba/search?q=early+ovarian+cancer+cg+chemotherapy&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjFyKfoirjeAhWno4sKHZK0AZkQ_AUIDigB&biw=1396&bih=686#imgrc=WLWzdK9lLJdpMM:
        
        IICG, 6c kl +(-cis, IA, IB, 85 pts, DFS 80vs 60SS, OS 80vs80%
        
        GOG 157
        
        https://www.google.ba/search?q=gog+157+study&tbm=isch&source=lnms&sa=X&ved=0ahUKEwiG9tLF2cTZAhXD_KQKHeHoCr0Q_AUICigB&biw=1229&bih=607&dpr=1.56#imgrc=ILdFTLVVFVLE_M:
  - - - podjela
        
        rekuretni
        
        od 2000 kronizacija bolesti
        
        OS 45mj, OS rek 25 mj, DFS 15 mj
        
        platinum sen
        
        studije
        
        SEER, OS, platinum mono HR 0.75, mix HR 0.50-Champara
        
        meta analiza - Raja, platinum mix vs mono, OS HR 0.8, PFS HR 0.7, neovisno o TFIp, prethodnim linijama
        
        toxičnost (brojevi se odnose na hipersenzitivnost)
        
        studije
        
        3 more items...
        
        prema mjesecima (0-6-12)
        
        rezistentni
        
        kemoth
        
        4 cito
        
        PLD
        
        pakli
        
        topo
        
        gem
        
        zajedničko: f3, RR<20%, PFS 3-4mj, OS 12 mj
        
        senzitivni
        
        do 1990 WAi, melfalan, ciklo-nezadovoljavajući
        
        AO-CTG, 991, meta analiza 45 studija, 800 pts, Cis bolji od nec, Cisvs Carbo isit efekt
        
        potvrda, SWOG, NCI
        
        ICON II, Europa, Carbo vs CAP, bolji car
        
        mednet
        
        https://www.themednet.org/search/siteSearch?refinementList%5Btopics.topic%5D%5B0%5D=Gynecologic%20Cancers&query=platinum%20senzitive
    - - EORTIC 55955, MRC OV 05 - 400 pts, HR 1.0, rana vs kasna kemoth za OS 26 vs 27; 2017 - 5 Ovarian Konference- za porast CA 125 bez simptoma i jerljive bolesti preporuka prćenje ili Tamxifen
        
        ![preuzmi (19)](https://coggle-i
      - od povećanog CA 125 do PD 5 mj (2 do kliničke PD)
  - - - **Postoperativna
        
        faza 3, lipo Doxo+carbo vs TC; manje neuropatije i alopacije
        
        Katsumata DD
        
        broj ciklusa kemoth
        
        indikacije
        
        protokoli
        
        IP, pakli iv (zbog sistmske kontrole)
        
        lošije ECOG kod starijih tjedni Carbo+pakli; MITO 7
        
        kod većeg rizika neuropatije Doxo ili Doce
        
        st III, GOG 172, 16 mj IP benefit
        
        praćenje?
      - **Neoadjuvatna
        
        protokolu
        
        faza 2, bev +/-TC, PFS = ali kirurška izvodljivost poboljašana sa bevom
        
        lipo doxo+carbo
        
        TC
        
        tm markeri CA 125, CEA
        
        PHD/cito verifikacija
        
        indikacije
- - - - http://www.primeoncology.org/online-education/solid-tumor/gyn-conference-2018-slides/harter/
    - - sumarizirano
        
        http://sci-hub.tw/10.1038/nrdp.2016.62
      - sve
        
        http://sci-hub.tw/10.1038/nrdp.2016.61
  - - - negativne studije
        
        endotelna stanica
        
        https://www.google.ba/search?q=ovarian+cancer+target+therapy&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjXu6KRj-raAhXpO5oKHdsGC6AQ_AUICigB&biw=1229&bih=548#imgrc=bcy9Ak7Yth4pCM:
      - stanica
- - - - **Nekompletna operacija/staging
        
        nakon 3 ckl kt, može i nakon 4-6 ckl
        
        za st II-IV
        
        rezidualna bolest
        
        https://www.google.ba/search?q=residual+disease+and+ovarian+cancer&source=lnms&tbm=isch&sa=X&ved=0ahUKEwiYtMeggrjeAhXpoIsKHUaWCjcQ_AUIDigB&biw=1396&bih=686#imgrc=U0-C9QGHo29yUM:
      - **Intervalna
        
        sekundarna CRS
        
        kandidati
        
        vrijeme relapsa
        
        6-12 mj, samo jedna meta
        
        12-30 mj - jedna ili multiple, ne karcinomatozu
        
        30 mj svi (čak i karcinomatoza
        
        studije
        
        GOG 213
        
        rezultati
        
        https://www.avastin-hcp.com/indications/ovar/efficacy-data.html
        
        dizajn
        
        https://www.google.ba/search?q=gog+213+study+results&source=lnms&tbm=isch&sa=X&ved=0ahUKEwj9mJqEgLjeAhWhiIsKHbYdCgQQ_AUIDigB&biw=1396&bih=686#imgrc=79fF-kvbOCBY1M:
        
        https://www.google.ba/search?q=gog+213+study&source=lnms&tbm=isch&sa=X&ved=0ahUKEwi3qJyg_7feAhVyqIsKHXIjBL0Q_AUIDigB&biw=1396&bih=686#imgrc=l58fgZybp1qy3M:
        
        https://www.youtube.com/watch?v=BJ6mKz1tZpo
        
        u tijek, sek OP+/- na KT +/- bev, 600 pts
        
        studija
        
        https://sci-hub.tw/10.1016/S1470-2045(17)30279-6
        
        AGO DESKTOP III
        
        zaključci
        
        https://www.google.ba/search?q=ago+desktop+III+study&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjDx5TugLjeAhUGqYsKHezjAyAQ_AUIDigB&biw=1396&bih=686#imgrc=Z-JIyVqz7bqZIM:
        
        dizajn
        
        https://www.google.ba/search?q=ago+desktop+III+study&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjDx5TugLjeAhUGqYsKHezjAyAQ_AUIDigB&biw=1396&bih=686#imgrc=JfZq-YZkEj7aVM:
        
        f3, platinum senzitivni, PFS 20 vs 15 mj, interim SS, prim OS čeka se, 400 pts, 60d smrtnost 0.5 vs 0
        
        povijest
        
        1995 de Borg OS 6 m> (neoptimalna primarna)
        
        GOG 152
        
        =OS, PFS
      - **Debulking
        
        NCCN, MS9
        
        postupak
        
        LČ
        
        kod
        
        izvan zdjelice + čvorovi (2 cm ili manji)
        
        pelvični i PA
        
        histerektomija
        
        rijetko supracervikalna
        
        totalna
        
        citološka analiza
        
        nema utjecaja za proširenu bolest
        
        ascites
        
        peirtonealni ispirak
        
        mogućnost R0- laparaoskopskom procjenom
        
        za klinički st II-IV; op gornjih abd meta; cilj RO
        
        primarna CRS
        
        relaps, 50-90%
        
        ovisi
        
        RO
        
        FIGO
        
        RR 50-80% CR
        
        IIIC
        
        R0-83 mj, 1-10 mm-53mj; >1 cm 49 mj, Silas 2017
        
        LION studija
        
        dizajn
        
        rezultati
        
        https://www.google.ba/search?biw=1396&bih=686&tbm=isch&sa=1&ei=G3jdW4WZKa3SrgTyxbTgAw&q=lion+study+ovarian+cancer&oq=lion+study+ovarian+cancer&gs_l=img.3...4513.7207.0.7308.15.8.0.0.0.0.0.0..0.0....0...1c.1.64.img..15.0.0....0.M8I3rD0bQtc#imgrc=AfVBj1nImISANM:
        
        https://www.google.ba/search?biw=1396&bih=686&tbm=isch&sa=1&ei=G3jdW4WZKa3SrgTyxbTgAw&q=lion+study+ovarian+cancer&oq=lion+study+ovarian+cancer&gs_l=img.3...4513.7207.0.7308.15.8.0.0.0.0.0.0..0.0....0...1c.1.64.img..15.0.0....0.M8I3rD0bQtc#imgrc=OKGgCYo--Gbr8M:
        
        ako LČ nisu poz ne limfadenektomija; 640 pts, IIB-IV, mOS 67mj, PFS 25mj, mLČ pelvis35, PA22 (traženo min 20p, PA 12); mikrmo meta LČ 56%, manje vrijeme OP, manje transfuzija
        
        prim op vs intervl OP
        
        TRUST
        
        https://pubmed.ncbi.nlm.nih.gov/31420412/
        
        Neoadjuvatna
        
        EORTC 55971, bez poboljšanja OS s NEO; 3 grupe: bez rez 45 (- 7 mj), 1-10 mm32 (-5mj), >1 cm 26(+1), 450 pts
        
        dizajn
        
        https://www.google.ba/search?q=eortc+55971&source=lnms&tbm=isch&sa=X&ved=0ahUKEwjRovrXi7jeAhWLlIsKHWe2CW0Q_AUIDygC&biw=1396&bih=686#imgrc=XeP_V9ln1MKuEM:
        
        retro analiza-stadij IV bolji OS za neo, st III bolji za op
        
        CHORUS, bez poboljšanja OS, HR 0.87 (cI 1.05)
        
        dizajn
        
        https://www.google.ba/search?hl=hr-BA&biw=1396&bih=686&tbm=isch&sa=1&ei=N4LdW_reFeLGrgTdvq_wBg&q=chorus+study+ovarian+cancer&oq=chorus+study+ovarian+cancer&gs_l=img.3...8392.15766.0.15945.27.24.0.0.0.0.1786.2788.0j8j8-1.9.0....0...1c.1.64.img..18.0.0....0.rwglwmgZKUg#imgrc=9AOZlQ_6r7bM2M:
        
        https://www.google.ba/search?hl=hr-BA&biw=1396&bih=686&tbm=isch&sa=1&ei=N4LdW_reFeLGrgTdvq_wBg&q=chorus+study+ovarian+cancer&oq=chorus+study+ovarian+cancer&gs_l=img.3...8392.15766.0.15945.27.24.0.0.0.0.1786.2788.0j8j8-1.9.0....0...1c.1.64.img..18.0.0....0.rwglwmgZKUg#imgrc=f1mmbsIDDGQWUM:
        
        SAD, single institucija studija; bolji oS za debulking kirurgiju
        
        Italijanksa studija, bolji OS za op
        
        JCOG0602
        
        SCORPION
        
        NE KANDIDATI ZA OP
        
        https://ascopubs.org/doi/full/10.1200/JCO.19.00022
- - - - 5 ovari konferencija-CA 125 visok
    - - Lendeman, KT vs tam, 2:1, PFS SS, OS nSS
- - - - 1 linija PFS 5 mj
    - - 1 L PFS 35 mj